Safety concerns with the long-term management of osteoporosis. - Wikidata - awgldk - TriplyDB

Safety concerns with the long-term management of osteoporosis.

Safety concerns with the long-term management of osteoporosis.

http://www.wikidata.org/entity/Q38101363

about

Antiresorptive drugs beyond bisphosphonates and selective oestrogen receptor modulators for the management of postmenopausal osteoporosis Qianggu capsule for the treatment of primary osteoporosis: evidence from a Chinese patent medicine.Asperosaponin VI promotes bone marrow stromal cell osteogenic differentiation through the PI3K/AKT signaling pathway in an osteoporosis model.New and emerging treatments for osteoarthritis management: will the dream come true with personalized medicine?Stem cell therapy for osteoporosis.Preventive effects of kudzu root on bone loss and cartilage degradation in ovariectomized rat Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures.Bone-protective Functions of Netrin 1 Protein.Enhanced immunoprotective effects by anti-IL-17 antibody translates to improved skeletal parameters under estrogen deficiency compared with anti-RANKL and anti-TNF-α antibodies.The guiding role of bone metabolism test in osteoporosis treatment.Protective Effects of Selected Botanical Agents on Bone.

P2860

Q33663460-54390B45-ABE8-4F87-BA09-BF03AC586F8B Q36279297-016747E2-E32F-46A5-AAA8-95EE97FB0D6E Q37348766-75555193-458B-44EE-A584-7EA00B8A2FC2 Q38138598-CD3AFC66-E38A-4E00-87CC-04A354CE198C Q38177180-5F96DA13-6ABC-4AF0-A327-3585C44CE542 Q41126673-E445D18E-78A9-49B1-A30C-C9BA1A3F7D00 Q45977053-CB1CECDF-7238-4A31-B4D8-CB98888FB23D Q46265917-C01B6E59-A63D-4EB9-B3AD-36BC9531BA84 Q53060269-D9E5B731-74C2-4F21-8202-F997B85D8D1C Q54956676-E83DE08A-18B2-4A86-88BC-4387D8640547 Q55040816-CD122185-A77A-429C-A411-DD39482397FD

P2860

Safety concerns with the long-term management of osteoporosis.

http://www.wikidata.org/entity/Q38101363

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Safety concerns with the long-term management of osteoporosis.

@en

type

label

Safety concerns with the long-term management of osteoporosis.

@en

prefLabel

Safety concerns with the long-term management of osteoporosis.

@en

P1433

Q38101363-3B6B458A-8A92-4808-A254-835E07AC5BE6

P1476

Q38101363-F9119DED-B910-4631-B5CC-117842907579

P2093

Q38101363-7F9A4D05-0A6E-4895-91F1-EDD1BA8B405A

Q38101363-A24EB443-8628-43ED-96D8-F7495111B69F

P2860

Q38101363-003449D3-B3F7-4D29-917C-E39A26F4AA98

Q38101363-029A6760-F618-49FF-A8D1-1DCF3BCD2A94

Q38101363-030CA74C-2897-4217-AD01-0DB2B9BFC012

Q38101363-034DE7CE-F99E-4E2A-8711-CEAB373A45E6

Q38101363-040A4DC5-3B2A-4A5C-BE2B-724513339EC2

Q38101363-0BF7AE8F-51AC-4F3D-A11B-F609FD2CA783

Q38101363-0C5CA616-664D-4D48-B0BC-C9F131A13ADD

Q38101363-0CB1D35E-7CBD-4C3A-8EC8-8ACE55DE315D

Q38101363-16C68E2B-A24D-44BA-92BC-E8C3A04ACD2B

Q38101363-17DAAE9B-E89D-43CB-893D-B4CB4B93A6A6

P304

Q38101363-8FF4AAE3-F19C-4D49-99DF-FD19A37F7E9A

P31

Q38101363-2906E013-CC45-4A73-AE02-A452C75BE68D

P356

Q38101363-2CB6681A-9E67-4148-A3FD-3CD060BE1CFE

P407

Q38101363-C3EFFD7F-86CE-43AB-9782-92370C2DA4C5

P433

Q38101363-1856082E-CC74-4246-B904-F29B0356C3D4

P478

Q38101363-4FA0BBAE-CCDB-4CFC-B37A-BC6355E60C74

P50

Q38101363-5793A362-08F1-49D0-A31D-5F4A247E5C89

P577

Q38101363-A2A7C380-9408-4401-8F37-96EA9473A75C

P698

Q38101363-80060861-651B-4AB9-AC8D-342FB3C50D9E

P921

Q38101363-0DEA423E-40F6-4CDA-BA99-9A5907E6FFD4

P356

14740338.2013.793669

P1433

Expert Opinion on Drug Safety

P1476

Safety concerns with the long-term management of osteoporosis.

@en

P2093

Franz Pelousse

http://www.w3.org/2001/XMLSchema#string

Olivier Bruyère

http://www.w3.org/2001/XMLSchema#string

P2860

European guidance for the diagnosis and management of osteoporosis in postmenopausal women

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

Lasofoxifene in postmenopausal women with osteoporosis

Continuing bisphosphonate treatment for osteoporosis--for whom and for how long?

Incidence of venous thromboembolism in users of strontium ranelate: an analysis of data from a prescription-event monitoring study in England.

Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group.

Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

P304

507-522

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14740338.2013.793669

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Yves Reginster

P577

2013-04-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23614635

http://www.w3.org/2001/XMLSchema#string

P921